{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:31:28Z","timestamp":1793320288115,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"vor","delay-in-days":450,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"TESARO, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1093\/annonc\/mdy181","type":"journal-article","created":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T07:08:55Z","timestamp":1525936135000},"page":"1784-1792","source":"Crossref","is-referenced-by-count":168,"title":["Safety and dose modification for patients receiving niraparib"],"prefix":"10.1016","volume":"29","author":[{"given":"J.S.","family":"Berek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.A.","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Peen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ghatage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mahner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lesoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Rosengarten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ellard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gonzalez-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Berton-Rigaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Madry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Reinthaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hazard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1093\/annonc\/mdy181_bb0010","first-page":"288","article-title":"Recurrent epithelial ovarian cancer: an update on treatment","volume":"27","author":"Foley","year":"2013","journal-title":"Oncology (Williston Park)"},{"issue":"5","key":"10.1093\/annonc\/mdy181_bb0015","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1758834014544121","article-title":"Treatment options in recurrent ovarian cancer: latest evidence and clinical potential","volume":"6","author":"Luvero","year":"2014","journal-title":"Ther Adv Med Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdy181_bb0020","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1093\/annonc\/mds203","article-title":"The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy","volume":"23","author":"Hanker","year":"2012","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy181_bb0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1359-6349(15)70005-4","article-title":"Limitations to the use of carboplatin-based therapy in advanced ovarian cancer","volume":"12","author":"Fotopoulou","year":"2014","journal-title":"EJC Suppl"},{"issue":"2","key":"10.1093\/annonc\/mdy181_bb0030","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2009.05.009","article-title":"Comparison of the quality of life of early and advanced stage ovarian cancer survivors","volume":"114","author":"Mirabeau-Beale","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdy181_bb0035","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/cncr.11291","article-title":"Psychological well being and quality of life in ovarian cancer survivors","volume":"98","author":"Ferrell","year":"2003","journal-title":"Cancer"},{"issue":"6","key":"10.1093\/annonc\/mdy181_bb0040","doi-asserted-by":"crossref","first-page":"E70","DOI":"10.1188\/07.ONF.E70-E81","article-title":"Transforming the death sentence: elements of hope in women with advanced ovarian cancer","volume":"34","author":"Reb","year":"2007","journal-title":"Oncol Nurs Forum"},{"issue":"16","key":"10.1093\/annonc\/mdy181_bb0045","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res"},{"issue":"9737","key":"10.1093\/annonc\/mdy181_bb0050","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"issue":"6","key":"10.1093\/annonc\/mdy181_bb0055","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1158\/1078-0432.CCR-11-2821","article-title":"A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas","volume":"18","author":"Kummar","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1093\/annonc\/mdy181_bb0060","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1093\/annonc\/mdy181_bb0065","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2017.08.022","article-title":"Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2","volume":"147","author":"Oza","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"19 Suppl","key":"10.1093\/annonc\/mdy181_bb0070","volume":"74","author":"Wang","year":"2014","journal-title":"Cancer Res"},{"issue":"9","key":"10.1093\/annonc\/mdy181_bb0075","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","article-title":"The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial","volume":"14","author":"Sandhu","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdy181_bb0080","article-title":"Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib results from the ENGOT-OV16\/NOVA Trial","author":"Oza","year":"2017","journal-title":"Presented at ESMO 2017 Congress"},{"issue":"10106","key":"10.1093\/annonc\/mdy181_bb0085","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"10.1093\/annonc\/mdy181_bb0090","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","article-title":"Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"17","author":"Ledermann","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy181_bb0095","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdy181_bb0100","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdy181_bb0105","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/S0959-8049(16)32967-7","article-title":"Evaluation of clinical-stage PARP inhibitors in cell-based assays to correlate PARP suppression with functional impact on DNA repair","volume":"69","author":"Wang","year":"2016","journal-title":"Eur J Cancer"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdy181_bb0110","first-page":"v330","article-title":"The exposure-response relationship of niraparib in patients with gBRCAmut and non-gBRCAmut: results from the ENGOT-OV16\/NOVA trial","volume":"28","author":"Wang","year":"2017","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419341092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419341092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/8\/1784\/25505110\/mdy181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T17:58:39Z","timestamp":1631815119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419341092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0923753419341092"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy181","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}